NDAORALTABLET1 Generic Approved
Approved
Apr 1955
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 6d ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESTINON (pyridostigmine bromide) is an oral anticholinesterase agent that facilitates neuromuscular transmission by inhibiting acetylcholinesterase, thereby preventing the destruction of acetylcholine at the myoneural junction. The product is primarily indicated for myasthenia gravis and reversal of nondepolarizing neuromuscular blocking agents during anesthesia. It demonstrates a longer duration of action and lower incidence of bradycardia and gastrointestinal stimulation compared to neostigmine, with a therapeutic index of approximately 1:6 for neuromuscular blockade reversal.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Testing Mestinon and Exercise in Fibromyalgia
Started Sep 2002
178 enrolled
Fibromyalgia
Career Relevance
Currently, no open job positions are linked to MESTINON (0 linked roles). Career opportunities would primarily involve generic pharmaceutical management, specialty pharmacy roles in myasthenia gravis therapy, or perioperative clinical positions. Relevant skills include neuromuscular disease expertise, hospital formulary management, and perioperative anesthesia knowledge.
Company
Worked on MESTINON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.